# Amyloid Prediction in Early Stage Alzheimer's Disease Through Speech Phenotyping - FUTURE Extension

> **NCT04951284** · — · TERMINATED · sponsor: **Novoic Limited** · enrollment: 42 (actual)

## Conditions studied

- Alzheimer Disease
- Preclinical Alzheimer's Disease
- Prodromal Alzheimer's Disease
- Alzheimer's Disease (Incl Subtypes)
- Mild Cognitive Impairment

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04951284
- **Lead sponsor:** Novoic Limited
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2021-01-21
- **Primary completion:** 2022-11-21
- **Final completion:** 2024-05-28
- **Target enrollment:** 42 (ACTUAL)
- **Why stopped:** Study only continued to 2 year follow-up.
- **Last updated:** 2024-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04951284

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04951284, "Amyloid Prediction in Early Stage Alzheimer's Disease Through Speech Phenotyping - FUTURE Extension". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04951284. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*